I Hate Dialysis Message Board
Dialysis Discussion => Dialysis: News Articles => Topic started by: okarol on August 06, 2013, 10:59:23 AM
-
INVESTING | 8/02/2013 @ 1:00PM |1,929 views
DaVita (DVA) Earnings Projected to Increase
By Narrative Science
Comment Now Follow Comments
Optimism surrounds DaVita DVA -0.6%, as it gets ready to report its second quarter results on Tuesday, August 6, 2013. Analysts are expecting the company to book a profit of $1.86 a share, up from $1.49 a year ago.
The consensus estimate has risen from three months ago when it was $1.85. It hasn’t been adjusted since. Analysts are expecting earnings of $7.53 per share for the fiscal year. Revenue is projected to be 49% above the year-earlier total of $1.93 billion at $2.88 billion for the quarter. For the year, revenue is projected to roll in at $11.55 billion.
Over the last four quarters, revenue has fallen an average of 25% year-over-year. The biggest drop came in the third quarter, when revenue fell 9% from the year-earlier quarter.
Revenue grew in the last two quarters. In the most recent quarter, revenue rose 47% year-over-year to $2.83 billion. The quarter before that, it rose 30%.
The majority of analysts (67%) rate DaVita as a buy. This compares favorably to the analyst ratings of its nearest five competitors, which average 60% buys.
Competitors in the healthcare sector include: Fresenius Medical Care AG & Co, Hanger Orthopedic Group and Universal Health UHS -0.92% Services.
Earnings estimates provided by Zacks.
Narrative Science, through its proprietary artificial intelligence platform, transforms data into stories and insights.
http://www.forbes.com/sites/narrativescience/2013/08/02/davita-dva-earnings-projected-to-increase/
-
The real question is "Given the pressure Obamacare will put on reimbursement rates, is this likely to continue, and is Davita a good stock to have in your portfolio?"
-
I'm glad I have stock!
:rofl;
Greedy Bastards!